CIP2A expression and localization in oral carcinoma and dysplasia.

Abstract:

AIMS:Oral squamous cell carcinoma (OSCC) is the most prevalent malignancy of the oral cavity resulting in severe morbidity and mortality. To date only few proteins have been suggested as potential biomarkers or targets for this type of cancer. Cancerous inhibitor of PP2A (CIP2A) is a protein expressed in epithelial tissues that stabilizes the oncogene c-Myc and causes cell transformation. This study was designed to investigate the expression of CIP2A in OSCC cell lines and tissues representing human normal, dysplasia and OSCC. METHODS:Using quantitative real time PCR, mRNA quantification for CIP2A was performed in a primary gingival cell line and OSCCs CAL 27 and SCC-25. Paraffin embedded human specimen classified as normal, dysplastic or OSCC were immunohistochemically stained for CIP2A expression. EGFR and CIP2A were also stained by immunofluorescence for co-localization. Samples of human normal oral tissue and OSCC were studied by PCR for mRNA expression of CIP2A. RESULTS:CIP2A was significantly increased in the human carcinoma cell lines compared to the primary gingival cell line. CIP2A was overexpressed in the human oral dysplasia and OSCC tissues compared to normal oral tissues. CIP2A was also preferentially localized in the dysplastic and OSCC epithelial areas compared to EGFR that was expressed mainly in areas of relatively normal epithelium and in dysplastic tissues above the basal layers. CONCLUSIONS:CIP2A may play a significant role in oral malignant transformation and therefore, it may be a potential target for chemotherapy of OSCC.

journal_name

Cancer Biol Ther

journal_title

Cancer biology & therapy

authors

Katz J,Jakymiw A,Ducksworth MK,Stewart CM,Bhattacharyya I,Cha S,Chan EK

doi

10.4161/cbt.10.7.12895

subject

Has Abstract

pub_date

2010-10-01 00:00:00

pages

694-9

issue

7

eissn

1538-4047

issn

1555-8576

pii

12895

journal_volume

10

pub_type

评论,杂志文章
  • Stromal-epithelial interactions are responsible for prostate tumor progression through an androgen-related mechanism.

    abstract::While several hypotheses have been put forward to explain how prostate tumors become resistant to androgen deprivation therapy, the mechanism by which prostate tumors have increased androgen concentrations as compared to the serum has been poorly explored. Using a stromal/epithelial cell co-culture model, Mizokami et ...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.9.3.11143

    authors: Sharma H,Sissung TM,Pressler H,Figg WD

    更新日期:2010-02-01 00:00:00

  • Exploiting defects in homologous recombination repair for metastatic, castration-resistant prostate cancer.

    abstract::The PROfound trial highlights that there is a benefit in testing genes involved in homologous recombination (HR) and forms the rationale for testing in all patients with metastatic, castration-resistant prostate cancer (mCRPC). This trial also demostrates that olaparib improves progression free survival (PFS), objecti...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2020.1809913

    authors: Chau V,Madan RA,Figg WD

    更新日期:2020-10-02 00:00:00

  • Selectively oncolytic mutant of HSV-1 lyses HeLa cells mediated by Ras/RTN3.

    abstract::The selectively oncolytic mtHSV, a HSV icp34.5 mutant with lacz gene insertion, was proved that it was targeted for treating tumors but not other organs, however, its oncolytic mechanism is under confirmation. The results showed that HeLa cells could be lysed efficiently by mtHSV in vitro. In the flow cytometry and We...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.6.2.3628

    authors: Su Y,Zhu H,Xiao W,Xu Q,Zhu L,Zhang X,Wan Q,Zhou S,Du E,Xu H,Yao L,Lv S,Hu B,Liu Y,Qi Y

    更新日期:2007-02-01 00:00:00

  • Acquired resistance of lung adenocarcinoma to EGFR-tyrosine kinase inhibitors gefitinib and erlotinib.

    abstract::Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, are the first targeted therapy drugs approved for the treatment of advanced non-small-cell lung cancer (NSCLC). Interestingly, treatment with these small molecule, reversible EGFR-TKIs leads to more positive respo...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章,评审

    doi:10.4161/cbt.9.8.11881

    authors: Xu Y,Liu H,Chen J,Zhou Q

    更新日期:2010-04-15 00:00:00

  • Epigenetic modulation of FBW7/Mcl-1 pathway for lung cancer therapy.

    abstract::Methylation induces epigenetic silencing of tumor suppressor genes in human lung cancer. Inhibition of DNA methyltransferases by decitabine (DAC) can demethylate and activate epigenetically silenced tumor suppressor genes. Epigenetic therapy using DAC should be an attractive strategy for lung cancer therapy. FBW7 is a...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2020.1856756

    authors: Kim MJ,Chen G,Sica GL,Deng X

    更新日期:2021-01-02 00:00:00

  • PIK3R3 promotes chemotherapeutic sensitivity of colorectal cancer through PIK3R3/NF-kB/TP pathway.

    abstract::Phosphoinositide-3-kinase regulatory subunit 3(PIK3R3) is overexpressed in different types of human cancer. We previously reported the important role of PIK3R3 in colorectal cancer (CRC). However, the prognosis effect of PIK3R3 in CRC is still remaining unclear. In this study, we explored online clinical databases to ...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2017.1416936

    authors: Ibrahim S,Li G,Hu F,Hou Z,Chen Q,Li G,Luo X,Hu J,Feng Y

    更新日期:2018-03-04 00:00:00

  • Bruton's tyrosine kinase is a potential therapeutic target in prostate cancer.

    abstract::Bruton's tyrosine kinase (BTK) is a non-receptor tyrosine kinase that has mainly been studied in haematopoietic cells. We have investigated whether BTK is a potential therapeutic target in prostate cancer. We find that BTK is expressed in prostate cells, with the alternate BTK-C isoform predominantly expressed in pros...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2015.1078023

    authors: Kokabee L,Wang X,Sevinsky CJ,Wang WL,Cheu L,Chittur SV,Karimipoor M,Tenniswood M,Conklin DS

    更新日期:2015-01-01 00:00:00

  • Enhanced growth inhibition and apoptosis induction in NSCLC cell lines by combination of celecoxib and 4HPR at clinically relevant concentrations.

    abstract::Celecoxib exhibits cancer preventive and therapeutic effects in animal models and clinical trials. It presumably acts through selective inhibition of cyclooxygenase-2 (COX-2) and subsequent reduction of prostaglandin (PG) synthesis. However, the concentrations of celecoxib required for growth inhibition and apoptosis ...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.4.4.1618

    authors: Sun SY,Schroeder CP,Yue P,Lotan D,Hong WK,Lotan R

    更新日期:2005-04-01 00:00:00

  • E2F1 as a target: promoter-driven suicide and small molecule modulators.

    abstract::Decreased requirements for mitogens and diminished sensitivity to antiproliferative signals are among the hallmarks of human cancer. These attributes are due, at least partly, to mutations that directly or indirectly compromise the function of the retinoblastoma tumor suppressor protein (pRB), which is a negative regu...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章,评审

    doi:

    authors: Kaelin WG Jr

    更新日期:2003-07-01 00:00:00

  • Sorafenib and pemetrexed toxicity in cancer cells is mediated via SRC-ERK signaling.

    abstract::The present studies sought to further understand how the anti-folate pemetrexed and the multi-kinase inhibitor sorafenib interact to kill tumor cells. Sorafenib activated SRC, and via SRC the drug combination activated ERK1/2. Expression of dominant negative SRC or dominant negative MEK1 abolished drug-induced ERK1/2 ...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.20562

    authors: Bareford MD,Hamed HA,Allegood J,Cruickshanks N,Poklepovic A,Park MA,Ogretmen B,Spiegel S,Grant S,Dent P

    更新日期:2012-07-01 00:00:00

  • Inactivation of miR-100 combined with arsenic treatment enhances the malignant transformation of BEAS-2B cells via stimulating epithelial -mesenchymal transition.

    abstract::Chronic arsenic treatment induces epithelial-mesenchymal transition (EMT) and promotes tumorigenicity, but the mechanism is unclear. MiR-100 has been shown to be involved in this biologic process. In this study, we hypothesize that inactivation of miR-100 combined with low concentration of arsenic exposure could promo...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2017.1345393

    authors: Yang J,Chen Z,Wang X,Xu M,Fang H,Li F,Liu Y,Jiang Y,Ding Y,Li J,Wang S

    更新日期:2017-12-02 00:00:00

  • Ras family signaling: therapeutic targeting.

    abstract::Mutationally activated and oncogenic versions of the ras genes were first identified in human tumors in 1982. This discovery prompted great interest in the development of anti-Ras strategies as novel, target-based approaches for cancer treatment. The three human ras genes represent the most frequently mutated oncogene...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章,评审

    doi:10.4161/cbt.306

    authors: Cox AD,Der CJ

    更新日期:2002-11-01 00:00:00

  • Indoleamine 2,3-dioxygenase (IDO) expression in lung cancer.

    abstract:BACKGROUND:The expression of indoleamine 2,3-dioxygenase (IDO) by tumor cells has been considered as a major tumor immune escape mechanism. The aim of this study was to investigate the expression of IDO in lung cancer cell lines as well as in surgically resected lung cancer specimens comparing the latter, to the expres...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.6.8.4446

    authors: Karanikas V,Zamanakou M,Kerenidi T,Dahabreh J,Hevas A,Nakou M,Gourgoulianis KI,Germenis AE

    更新日期:2007-08-01 00:00:00

  • Genetic polymorphisms in OGG1 and their association with angiomyolipoma, a benign kidney tumor in patients with tuberous sclerosis.

    abstract::The enzyme 8-oxoguanine glycosylase 1 (OGG1) repairs 8-oxo-2-deoxyguanosine residue (8-oxodG) an oxidatively damaged promutagenic base. Genetic variations in OGG1 gene have been shown to modulate DNA repair capacity and are related risk of tumor development. However, epidemiologic findings have been inconsistent. The ...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.7.1.5120

    authors: Habib SL,Danial E,Nath S,Schneider J,Jenkinson CP,Duggirala R,Abboud HE,Thameem F

    更新日期:2008-01-01 00:00:00

  • Chronic exposure to chewing tobacco selects for overexpression of stearoyl-CoA desaturase in normal oral keratinocytes.

    abstract::Chewing tobacco is a common practice in certain socio-economic sections of southern Asia, particularly in the Indian subcontinent and has been well associated with head and neck squamous cell carcinoma. The molecular mechanisms of chewing tobacco which leads to malignancy remains unclear. In large majority of studies,...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2015.1078022

    authors: Nanjappa V,Renuse S,Sathe GJ,Raja R,Syed N,Radhakrishnan A,Subbannayya T,Patil A,Marimuthu A,Sahasrabuddhe NA,Guerrero-Preston R,Somani BL,Nair B,Kundu GC,Prasad TK,Califano JA,Gowda H,Sidransky D,Pandey A,Chatterje

    更新日期:2015-01-01 00:00:00

  • Dissecting the roles of E1A and E1B in adenoviral replication and RCAd-enhanced RDAd transduction efficacy on tumor cells.

    abstract::Oncolytic viruses have recently received widespread attention for their potential in innovative cancer therapy. Many telomerase promoter-regulated oncolytic adenoviral vectors retain E1A and E1B. However, the functions of E1A and E1B proteins in the oncolytic role of replication-competent adenovirus (RCAd) and RCAd en...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.29842

    authors: Wei F,Wang H,Chen X,Li C,Huang Q

    更新日期:2014-10-01 00:00:00

  • Small molecule inhibitors of IRES-mediated translation.

    abstract::Many genes controlling cell proliferation and survival (those most important to cancer biology) are now known to be regulated specifically at the translational (RNA to protein) level. The internal ribosome entry site (IRES) provides a mechanism by which the translational efficiency of an individual or group of mRNAs c...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2015.1071729

    authors: Vaklavas C,Meng Z,Choi H,Grizzle WE,Zinn KR,Blume SW

    更新日期:2015-01-01 00:00:00

  • Gefitinib-sensitizing mutation in esophageal carcinoma cell line Kyse450.

    abstract:PURPOSE:The sensitivity of lung cancer to gefitinib has been found to be associated with mutations at the tyrosine kinase domain of epidermal growth factor receptor (EGFR), yet similar observations are not available in other solid tumors. We recently identified mutations in the EGFR kinase domain in primary esophageal ...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.5.2.2318

    authors: Guo M,Liu S,Herman JG,Zhuang H,Lu F

    更新日期:2006-02-01 00:00:00

  • Chemo-resistant melanoma sensitized by tamoxifen to low dose curcumin treatment through induction of apoptosis and autophagy.

    abstract::Melanoma is the deadliest form of skin cancer, which is notoriously aggressive and chemo-resistant, and for which there is little effective treatment available if it goes undetected. Curcumin from the turmeric spice (Curcuma longa) has long been used in Southeast Asian medicine to alleviate ailments and cure an array ...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.11.2.13798

    authors: Chatterjee SJ,Pandey S

    更新日期:2011-01-15 00:00:00

  • Aggressive myeloid leukemia formation is directed by the Musashi 2/Numb pathway.

    abstract::Chronic myeloid leukemia (CML) progresses from a chronic phase to a deadly blast crisis phase. While it is known that BCR-ABL initiates the disease and that secondary molecular and genetic abnormalities likely contribute to progression of the disease to blast crisis, details regarding the mechanism(s) of blast phase p...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.10.10.14010

    authors: Griner LN,Reuther GW

    更新日期:2010-11-15 00:00:00

  • Multiplying therapies and reducing toxicity in metastatic melanoma.

    abstract::Prior to 2011, only 2 systemic treatments were approved for the treatment of melanoma and these had limited efficacy. In the past 4 years, 6 novel agents have received FDA approval. Herein, we will focus on 4 recently published NEJM papers reporting the results of clinical trials, comprising 4 agents targeting the MAP...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2015.1046650

    authors: Massey PR,Prasad V,Figg WD,Fojo T

    更新日期:2015-01-01 00:00:00

  • Interferon-alpha induces TRAIL expression and cell death via an IRF-1-dependent mechanism in human bladder cancer cells.

    abstract::Apoptosis induced by interferon-alpha (IFNalpha) is associated with induction of TRAIL in a number of different cell types. Here we examined whether or not TRAIL was required for apoptosis in a model human bladder cancer cell line (UM-UC-12) and defined the molecular mechanisms involved in IFNalpha-induced TRAIL expre...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.6.6.4088

    authors: Papageorgiou A,Dinney CP,McConkey DJ

    更新日期:2007-06-01 00:00:00

  • Increasing the therapeutic index of 5-fluorouracil and 6-thioguanine by targeting loss of MTAP in tumor cells.

    abstract::Methylthioadenosine phosphorylase (MTAP), a key enzyme in the catabolism of 5'-deoxy-5'-methylthioadenosine (MTA), catalyzes the formation of adenine and 5-methylthioribose-1-phosphate. MTAP is expressed in all cells throughout the body, but a significant percentage of human tumors have lost MTAP expression, thereby m...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.21115

    authors: Tang B,Testa JR,Kruger WD

    更新日期:2012-09-01 00:00:00

  • Inhibition of Hsp27 and Hsp40 potentiates 5-fluorouracil and carboplatin mediated cell killing in hepatoma cells.

    abstract::Heat shock proteins (Hsps) modulate several cellular functions and are ubiquitously present in cell. Here, we investigated alterations in the expression of Hsps and explored functional consequences of the same. Moreover, effect of quercetin (Qctn), an inhibitor of Hsps, on chemotherapeutic drugs treatment in hepatoma ...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.8.22.9687

    authors: Sharma A,Upadhyay AK,Bhat MK

    更新日期:2009-11-01 00:00:00

  • The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines.

    abstract::We investigated the cytotoxic interactions of romidepsin, a histone deacetylase inhibitor, and lenalidomide, an immunomodulatory agent, in a T-cell lymphoma preclinical model. Hut-78 and Karpas-299 cells were treated with romidepsin and lenalidomide alone and in combination. The interaction between romidepsin and lena...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2016.1219820

    authors: Cosenza M,Civallero M,Fiorcari S,Pozzi S,Marcheselli L,Bari A,Ferri P,Sacchi S

    更新日期:2016-10-02 00:00:00

  • Effect of DNAzymes targeting Akt1 on cell proliferation and apoptosis in nasopharyngeal carcinoma.

    abstract::The phosphoinositide 3-kinase (PI3K)/Akt signaling pathway is important in nasopharyngeal carcinoma (NPC) pathogenesis. Activated PI3K and its downstream target Akt are concernful signaling molecules and key survival factors involved in the control of cell proliferation, apoptosis and oncogenesis. The protein kinase A...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.8.4.7433

    authors: Yang L,Xiao L,Ma X,Tang M,Weng X,Chen X,Sun L,Cao Y

    更新日期:2009-02-01 00:00:00

  • Tumor suppressor activities of the Fbw7 E3 ubiquitin ligase receptor.

    abstract::The F-box protein Fbw7/Sel-10/hCdc4/Ago, which is known to regulate ubiquitination and degradation of numerous important regulators of cell division and death including Notch, cyclin E, c-Jun and c-Myc, has been recently rediscovered as a p53-dependent tumor suppressor. Delineation of the mechanisms of Fbw7 anti-oncog...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章,评审

    doi:10.4161/cbt.4.5.1703

    authors: Fuchs SY

    更新日期:2005-05-01 00:00:00

  • c-Myc modulation: a key role in melanoma drug response.

    abstract::Understanding molecular mechanisms involved in melanoma resistance to drugs is a big challenge. Experimental evidences suggested a correlation between mutational status in B-RAF and melanoma cell susceptibility to drugs, such as paclitaxel, doxorubicin and temozolomide, which generate an accumulation of hydrogen perox...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2015.1030546

    authors: Fico A,Alfano D,Valentino A,Vasta V,Cavalcanti E,Travali S,Patriarca EJ,Caputo E

    更新日期:2015-01-01 00:00:00

  • Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo.

    abstract::The present studies have examined approaches to suppress MCL-1 function in breast cancer cells, as a means to promote tumor cell death. Treatment of breast cancer cells with CDK inhibitors (flavopiridol; roscovitine) enhanced the lethality of the ERBB1 inhibitor lapatinib in a synergistic fashion. CDK inhibitors inter...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.10.9.13273

    authors: Mitchell C,Yacoub A,Hossein H,Martin AP,Bareford MD,Eulitt P,Yang C,Nephew KP,Dent P

    更新日期:2010-11-01 00:00:00

  • Microarray expression profiling of dysregulated long non-coding RNAs in triple-negative breast cancer.

    abstract::Triple-negative breast cancer (TNBC) represents a collection of malignant breast tumors that are often aggressive and have an increased risk of metastasis and relapse. Long non-coding RNAs are generally defined as RNA transcripts measuring 200 nucleotides or longer that do not encode for any protein. During the past d...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2015.1040957

    authors: Chen C,Li Z,Yang Y,Xiang T,Song W,Liu S

    更新日期:2015-01-01 00:00:00